PharmaShots | Incisive News in 3 Shots

Subscribe Now

KEYTRUDA

Astellas & Seagen Reports the US FDA’s Acceptance of sBLA with Priority Review for Padcev (enfortumab vedotin-ejfv) + Keytruda to Treat Urothelial Cancer

Astellas & Seagen Reports the US FDA’s Acceptance of sBLA with Priority Review for Padcev (enfortumab vedotin-ejfv) + Keytruda to...

December 1, 2023

Insights+: EMA Marketing Authorization of New Drugs in October 2023

Insights+: EMA Marketing Authorization of New Drugs in October 2023

November 23, 2023

Insights+: The US FDA New Drug Approvals in April 2023

Insights+: The US FDA New Drug Approvals in April 2023

May 17, 2023

Xbrane Biopharma Seeks to Initiate the Development of Keytruda and Darzalex Biosimilar

Xbrane Biopharma Seeks to Initiate the Development of Keytruda and Darzalex Biosimilar

December 13, 2021

Merck Enters in Third Clinical Trial Collaboration with Adagene to Advance ADG106 + Keytruda (pembrolizumab) for Solid Tumors and Hematological Malignancies

Merck Enters in Third Clinical Trial Collaboration with Adagene to Advance ADG106 + Keytruda (pembrolizumab) for Solid Tumors and...

August 19, 2021

Astellas and Seagen Report Updated Results of Padcev in Two Studies for Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy

Astellas and Seagen Report Updated Results of Padcev in Two Studies for Locally Advanced or Metastatic Urothelial Cancer Not Eligi...

May 21, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us